Facebook
Twitter
Telegram
Report an ErrorCymaBay Therapeutics Balance Sheet 2011-2024 | CBAY
Annual Balance Sheet CymaBay Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-206 M | -19.6 M | -125 M | -26.4 M | -22.7 M | -49 M | -17 M | -1.7 M | 1.6 M | -7.08 M | -20 M | 6.01 M | - |
Long Term Debt |
467 K | 30 K | 695 K | - | - | - | 2.99 M | 6.1 M | 8.8 M | 3.15 M | 4.41 M | - | - |
Long Term Debt Current |
7 K | 664 K | 567 K | 482 K | 407 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 1.26 M | 1.74 M | 1.91 M | 2.99 M | 6.11 M | 8.82 M | 3.16 M | 4.42 M | 319 M | - |
Total Current Liabilities |
36.8 M | 15.4 M | 18.4 M | 9.86 M | 17.6 M | 14.4 M | 16.3 M | 9.31 M | 6.15 M | 20.5 M | 9.49 M | - | - |
Total Liabilities |
142 M | 106 M | 69.4 M | 11.1 M | 19.4 M | 16.3 M | 19.3 M | 15.4 M | 15 M | 23.6 M | 13.9 M | 337 M | - |
Deferred Revenue |
1.69 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-978 M | -873 M | -767 M | -677 M | -626 M | -523 M | -451 M | -423 M | -396 M | -381 M | -349 M | -329 M | - |
Total Assets |
435 M | 142 M | 202 M | 154 M | 206 M | 187 M | 104 M | 19.4 M | 43.1 M | 37.5 M | 32.5 M | 8.12 M | - |
Cash and Cash Equivalents |
207 M | 20.3 M | 126 M | 28.2 M | 24.9 M | 49 M | 23.1 M | 10.5 M | 7.71 M | 11.6 M | 24.4 M | 7.73 M | - |
Book Value |
292 M | 36.2 M | 133 M | 143 M | 186 M | 170 M | 84.9 M | 3.94 M | 28.1 M | 13.8 M | 18.6 M | -329 M | - |
Total Shareholders Equity |
292 M | 36.2 M | 133 M | 143 M | 186 M | 170 M | 84.9 M | 3.94 M | 28.1 M | 13.8 M | 18.6 M | -329 M | - |
All numbers in USD currency
Quarterly Balance Sheet CymaBay Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 30 K | 206 K | 374 K | 537 K | 695 K | 844 K | 988 K | 1.13 M | 1.26 M | 1.26 M | 1.26 M | 1.26 M | 1.74 M | 1.74 M | 1.74 M | 1.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
125 M | 118 M | 141 M | 106 M | 99.1 M | 95.3 M | 93.3 M | 69.4 M | 35.8 M | 9.95 M | 9.04 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15 M | 15 M | 15 M | 15 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 18 M | 18 M | - | - | - | - | - | - |
Deferred Revenue |
1.63 M | 1.63 M | 33.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 207 K | 207 K | 207 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-936 M | -902 M | -902 M | -873 M | -846 M | -822 M | -795 M | -767 M | -740 M | -718 M | -694 M | -677 M | -677 M | -677 M | -677 M | -626 M | -626 M | -626 M | -626 M | -523 M | -523 M | -523 M | -523 M | -451 M | -451 M | -451 M | -451 M | -423 M | -423 M | -423 M | -423 M | -396 M | -396 M | -396 M | -396 M | -381 M | -381 M | -381 M | -381 M | -349 M | -349 M | -349 M | -349 M | -329 M | -329 M | - | - | - | - | - | - |
Total Assets |
451 M | 227 M | 245 M | 142 M | 159 M | 178 M | 201 M | 202 M | 123 M | 117 M | 137 M | 154 M | 154 M | 154 M | 154 M | 206 M | 206 M | 206 M | 206 M | 187 M | 187 M | 187 M | 187 M | 104 M | 104 M | 104 M | 104 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 43.1 M | 43.1 M | 43.1 M | 43.1 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 8.12 M | 8.12 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
274 M | 35.5 M | 59.2 M | 20.3 M | 30.7 M | 52.8 M | 74 M | 126 M | 69 M | 32.9 M | 43.3 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 49 M | 49 M | 49 M | 49 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 7.71 M | 7.71 M | 7.71 M | 7.71 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 7.73 M | 7.73 M | - | - | 8.02 M | - | - | - |
Book Value |
326 M | 108 M | 104 M | 36.2 M | 60.2 M | 82.5 M | 107 M | 133 M | 87.1 M | 107 M | 128 M | 143 M | 143 M | 143 M | 143 M | 186 M | 186 M | 186 M | 186 M | 170 M | 170 M | 170 M | 170 M | 84.9 M | 84.9 M | 84.9 M | 84.9 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | -9.87 M | -9.87 M | - | - | - | - | - | - |
Total Shareholders Equity |
326 M | 108 M | 104 M | 36.2 M | 60.2 M | 82.5 M | 107 M | 133 M | 87.1 M | 107 M | 128 M | 143 M | 143 M | 143 M | 143 M | 186 M | 186 M | 186 M | 186 M | 170 M | 170 M | 170 M | 170 M | 84.9 M | 84.9 M | 84.9 M | 84.9 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 18.6 M | 20.1 M | 18.6 M | 18.6 M | -329 M | -329 M | - | - | -305 M | - | - | - |
All numbers in USD currency